[go: up one dir, main page]

WO1996001430A3 - Screening for nuc inhibitors - Google Patents

Screening for nuc inhibitors Download PDF

Info

Publication number
WO1996001430A3
WO1996001430A3 PCT/US1995/008328 US9508328W WO9601430A3 WO 1996001430 A3 WO1996001430 A3 WO 1996001430A3 US 9508328 W US9508328 W US 9508328W WO 9601430 A3 WO9601430 A3 WO 9601430A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuc
protein
screening
agents
inhibitors
Prior art date
Application number
PCT/US1995/008328
Other languages
French (fr)
Other versions
WO1996001430A2 (en
Inventor
Ranjan Mukherjee
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Priority to EP95925440A priority Critical patent/EP0769146A2/en
Priority to JP8503950A priority patent/JPH10502454A/en
Priority to AU29571/95A priority patent/AU2957195A/en
Publication of WO1996001430A2 publication Critical patent/WO1996001430A2/en
Publication of WO1996001430A3 publication Critical patent/WO1996001430A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

This invention provides methods for screening for agents useful for treatment of diseases and pathological conditions affected by the level of NUC protein activity. These agents reduce or relieve the repression of PPARα protein and TR protein transcription activation activity by NUC protein. The selected novel or unique agents can be used to treat hyperlipidemia, hypercholesteremia and hyperlipoproteinemia.
PCT/US1995/008328 1994-07-01 1995-06-29 Screening for nuc inhibitors WO1996001430A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95925440A EP0769146A2 (en) 1994-07-01 1995-06-29 Screening for nuc inhibitors
JP8503950A JPH10502454A (en) 1994-07-01 1995-06-29 Screening for NUC inhibitors
AU29571/95A AU2957195A (en) 1994-07-01 1995-06-29 Screening for nuc inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27063594A 1994-07-01 1994-07-01
US08/270,635 1994-07-01

Publications (2)

Publication Number Publication Date
WO1996001430A2 WO1996001430A2 (en) 1996-01-18
WO1996001430A3 true WO1996001430A3 (en) 1996-10-10

Family

ID=23032149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008328 WO1996001430A2 (en) 1994-07-01 1995-06-29 Screening for nuc inhibitors

Country Status (5)

Country Link
EP (1) EP0769146A2 (en)
JP (1) JPH10502454A (en)
AU (1) AU2957195A (en)
CA (1) CA2193685A1 (en)
WO (1) WO1996001430A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US7635708B2 (en) 1996-12-11 2009-12-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
EP1083891B1 (en) 1998-06-02 2003-03-12 Arthromics PLC Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease
DE602005024836D1 (en) 2004-09-16 2010-12-30 Merck Sharp & Dohme COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011974A2 (en) * 1993-10-22 1995-05-04 Ligand Pharmaceuticals, Inc. Human peroxisome proliferator activated receptor
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
WO1996001317A2 (en) * 1994-07-01 1996-01-18 The Salk Institute For Biological Studies Mammalian peroxisome proliferator-activated receptors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011974A2 (en) * 1993-10-22 1995-05-04 Ligand Pharmaceuticals, Inc. Human peroxisome proliferator activated receptor
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
WO1996001317A2 (en) * 1994-07-01 1996-01-18 The Salk Institute For Biological Studies Mammalian peroxisome proliferator-activated receptors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. SCHMIDT ET AL.: "Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.", MOLECULAR ENDOCRINOLOGY, vol. 6, no. 10, 1992, WASHINGTON DC USA, pages 749 - 784, XP000579262 *
F. CHEN ET AL.: "Identification of two mPPAR related receptors and evidence for the existence of five subfamily members", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 196, no. 2, 1993, NEW YORK NY USA, pages 671 - 677, XP000577084 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635708B2 (en) 1996-12-11 2009-12-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor

Also Published As

Publication number Publication date
CA2193685A1 (en) 1996-01-18
JPH10502454A (en) 1998-03-03
AU2957195A (en) 1996-01-25
EP0769146A2 (en) 1997-04-23
WO1996001430A2 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
ATE321548T1 (en) USE OF STATIN TO TREAT SKIN DISEASES
ZA971937B (en) Combinations for treatment of proliferative diseases.
DE69936335D1 (en) USE OF MORPHOLINOL FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISORDERS
GB9323165D0 (en) Compounds
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
ATE527022T1 (en) USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT AND PREVENTION OF TUMORS, TUMOR-DEPENDENT DISEASES AND CACHEXIA
DE69626539D1 (en) topical use of vitamin D for the treatment of eye diseases
EE9900036A (en) Novel compounds and compositions for the treatment of diseases associated with tryptase activity
WO2001021647A3 (en) Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
DE69830069D1 (en) USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF HYPOXIA OR REDUCED METABOLISM
DE69635708D1 (en) TETRANDRIN FOR THE TREATMENT OF EYE IGNITIONS
ATE201992T1 (en) CARBOSTYRIL DERIVATIVE FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES
MA25404A1 (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS.
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
ATE214272T1 (en) TOPICAL USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT EYE PAIN
DE59707519D1 (en) USE OF 1-HYDROXY-2-PYRIDONES FOR TREATING SKIN INFECTIONS
DE69638281D1 (en) Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for the treatment of bronchial hyperreactivity
ATE173620T1 (en) USE OF AN ANTAGONIST OF TNF-ALPHA FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN
DE69807466D1 (en) TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO1996001430A3 (en) Screening for nuc inhibitors
DE69729735D1 (en) USE OF BENZOPYRANOLS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE69735417D1 (en) 2,5-DIHYDROXYBENZYLSULFON DERIVATIVES FOR THE TREATMENT OF SEXUAL DISORDERS
DE69822297D1 (en) TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DE69924284D1 (en) USE OF STIMULATORS OF NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEEGENERATIVE OPHTHALMIC DISEASES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CN CZ ES FI GE HU IS JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL PT RO RU SD SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CN CZ ES FI GE HU IS JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL PT RO RU SD SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2193685

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995925440

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995925440

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995925440

Country of ref document: EP